SCHEMBL7705559

SCHEMBL7705559

CC(=O)Nc1ccc(Sc2ccc(C(=O)N[C@@H]3C4CCN(CC4)[C@H]3C)cc2)nc1.C[C@H]1[C@H](NC(=O)c2ccc(Sc3ccc(C#N)cn3)cc2)C2CCN1CC2.C[C@H]1[C@H](NC(=O)c2ccc(Sc3ccc(N4CCOCC4)cn3)cc2)C2CCN1CC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.38
USP30 Q70CQ3 1/20 0.37
MAPT P10636 8/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 3/20 0.37
ATM Q13315 1/20 0.37
KDR P35968 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HTT P42858 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
LRRK2 Q5S007 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
PLK4 O00444 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6883162 0.88 CHRNA7 (0.42) USP30MAPTALDH1A1LMNAATM
SCHEMBL6882041 0.85 CHRNA7 (0.43) NPC1RAB9A
SCHEMBL6884412 0.84 CHRNA7 (0.44) KDR
SCHEMBL7703079 0.79 USP30 (0.39) PPARGUSP30KDRHTTPLK4
SCHEMBL6879559 0.76 CHRNA7 (0.41) USP30MAPTATMNPC1TP53
SCHEMBL6878278 0.75 CHRNA7 (0.46) KDR
SCHEMBL6883586 0.75 CHRNA7 (0.46) ALDH1A1LMNANPC1RAB9A
SCHEMBL6884099 0.74 CHRNA7 (0.46) USP30MAPTALDH1A1LMNAATM
SCHEMBL6882524 0.74 CHRNA7 (0.47) ALDH1A1NPC1HPGD
SCHEMBL6882534 0.74 CHRNA7 (0.46) LMNAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486172-B2 ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF BENZAMIDE OR BENZOCARBONYLSULFIDE SUBSTITUTED 1-AZABICYCLO(2,2,2)OCT-3-YL COMPOUNDS TO TREAT THE CONDITIONS ASSOCIATED WITH DEFECTS OF NICOTINIC SUBTYPES BRAIN RECEPTORS PHARMACIA & UPJOHN COMPANY 2002-11-26 US claimed